Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Neoadjuvant for Salivary Gland Cancer
NCT05000892Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in salivary gland cancer (SGC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Adverse events graded by CTCAE v5.0 at 90 days and Percentage of participants demonstrating pathological response. Started Dec 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT05000892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000892.